{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:53:01Z","timestamp":1795114381622,"version":"4.10.3"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.critrevonc.2023.103962","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T03:33:25Z","timestamp":1678764805000},"page":"103962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Survival differences between HER2-0 and HER2-low-expressing breast cancer \u2212 A meta-analysis of early breast cancer patients"],"prefix":"10.1016","volume":"185","author":[{"given":"Ciqiu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minting","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9851-7080","authenticated-orcid":false,"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2023.103962_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-021-06365-7","article-title":"HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer","volume":"190","author":"de Moura Leite","year":"2021","journal-title":"Breast Cancer Res Treat."},{"issue":"20","key":"10.1016\/j.critrevonc.2023.103962_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff AC","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103962_bib3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/cancers13051015","article-title":"The Exciting New Field of HER2-Low Breast Cancer Treatment","volume":"13","author":"Eiger","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2023.103962_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103962_bib5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2 low positive breast cancer pooled analysis of individual patients data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert C","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103962_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.103962_bib7","doi-asserted-by":"crossref","unstructured":"Xu H., Han Y., Wu Y., et al. Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience. Front Oncol. 2022;12:906011. Published 2022 Jun 16. doi:10.3389\/fonc.2022.906011.","DOI":"10.3389\/fonc.2022.906011"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103962_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","article-title":"Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status","volume":"20","author":"Zhang G","year":"2022","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103962_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12916-022-02284-6","article-title":"HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis","volume":"20","author":"Tan RSYC","year":"2022","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103962_bib10","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/cancers13112824","article-title":"HER2-Low Breast Cancer: Molecular Characteristics and Prognosis","volume":"13","author":"Agostinetto","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"142","key":"10.1016\/j.critrevonc.2023.103962_bib11","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00432-016-2146-z","article-title":"HER2 neu score as a prognostic factor for outcome in patients with triple-negative breast cancer","volume":"6","author":"Schmidt G","year":"2016","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103962_bib12","doi-asserted-by":"crossref","unstructured":"C. Domergue et al. Impact of HER2 status (HER2-low versus HER2\u20130) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). 2021 ESMO VOLUME 32, SUPPLEMENT 5, S428-S429. Annals of Oncology.","DOI":"10.1016\/j.annonc.2021.08.437"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103962_bib13","article-title":"Impact of Human Epidermal Growth Factor receptor2 low status in response to neoadjuvant chemotherapy in early breast cancer","volume":"14","author":"Alves FR","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.critrevonc.2023.103962_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2022.06.012","article-title":"Long-term prognostic significance of HER2-low and HER2-zero in node negative breast cancer","author":"Almstedt","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.103962_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.2286","article-title":"Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer","author":"Tarantino","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.103962_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.breast.2021.08.016","article-title":"Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer","volume":"60","author":"Mutai R","year":"2021","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103962_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.21873\/cdp.10111","article-title":"Prognostic significance of low HER2 expression in patients with early hormone receptor positive breast cancer","volume":"2","author":"Douganiotis","year":"2022","journal-title":"Cancer Diagn. Progn."},{"issue":"23","key":"10.1016\/j.critrevonc.2023.103962_bib18","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.3390\/cancers13236059","article-title":"Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers","volume":"13","author":"Jacot W","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103962_bib19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s12282-022-01364-y","article-title":"Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer","volume":"29","author":"Chen","year":"2022","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103962_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12282-021-01303-3","article-title":"The Frequency of Low HER2 Expression in Breast Cancer and a comparison of prognosis between patients with HER2 low and HER2 negative breast cancer by HR status","volume":"29","author":"Horisawa N","year":"2022","journal-title":"Breast Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103962_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.clbc.2022.02.008","article-title":"Characteristics, Clinical Differences and Outcomes of Breast Cancer Patients with Negative or Low HER2 Expression","volume":"22","author":"Rosso","year":"2022","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103962_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13058-022-01519-x","article-title":"Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society","volume":"24","author":"Won","year":"2022","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.critrevonc.2023.103962_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney JF","year":"2007","journal-title":"Trials"},{"issue":"26","key":"10.1016\/j.critrevonc.2023.103962_bib24","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1200\/JCO.2011.40.5902","article-title":"A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2\u2013Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine","volume":"30","author":"Krop","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103962_bib25","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103962_bib26","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.2009.24.1661","volume":"28","author":"Gianni","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103962_bib27","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103962_bib28","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.103962_bib29","doi-asserted-by":"crossref","unstructured":"Shanu Modi, M. and M.M.Haeseong Park, Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. JOURNAL OF CLINICAL ONCOLOGY, 2020.","DOI":"10.1200\/JCO.19.02318"},{"issue":"34","key":"10.1016\/j.critrevonc.2023.103962_bib30","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, Double-Blind, Randomized Study Comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first line treatment for metastatic breast cancer","volume":"26","author":"Di Leo","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103962_bib31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) \u2013Positive Breast Cancer After Prior HER2-Directed Therapy","volume":"29","author":"Rd","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103962_bib32","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody\u2013drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.103962_bib33","first-page":"1455","article-title":"B-12 TALENT: Neoadjuvant trastuzumab deruxtecan (T-DXd) with or without anastrozole for HER2-low","author":"Hurvitz","year":"2022","journal-title":"HR+ Early-Stage Breast Cancer SABCS 2022 Abstr. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103962_bib34","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/annonc\/mdv611","article-title":"Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry","volume":"27","author":"Niikura","year":"2016","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103962_bib35","doi-asserted-by":"crossref","first-page":"9600","DOI":"10.18632\/oncotarget.3292","article-title":"Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study","volume":"6","author":"Jin","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103962_bib36","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jso.24762","article-title":"Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer","volume":"116","author":"Yoshida","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103962_bib37","doi-asserted-by":"crossref","unstructured":"Di\u00e9ras V., et al. Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY). 2021 SABCS abs PD8\u201302.","DOI":"10.1158\/1538-7445.SABCS21-PD8-02"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103962_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"26","key":"10.1016\/j.critrevonc.2023.103962_bib39","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2016.70.5319","article-title":"Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations","volume":"35","author":"Hanna","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:47:32Z","timestamp":1760903252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":39,"alternative-id":["S1040842823000501"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103962","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival differences between HER2-0 and HER2-low-expressing breast cancer \u2212 A meta-analysis of early breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103962"}}